
    
      This is an open, uncontrolled study to assess safety and tolerability of Fluval P monovalent
      influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing
      6 mcgHA per 0.5mL active ingredient in children of 6-36 months of age. The vaccination is not
      repeated.

      Tolerability and safety (incidence of adverse events) of the study drug is assessed after Day
      28 then after Day 180-210 following the vaccination.
    
  